89 related articles for article (PubMed ID: 20175827)
1. Anti-cytokeratin CAM 5.2 does not act as a surrogate of the cytokeratin 8/18 monoclonal antibody. Comment on: "Utility of p63 in the differential diagnosis of atypical fibroxanthoma and spindle cell squamous cell carcinoma", in J Cutan Pathol 2009; 36: 543.
Chen JT; Hsu JD; Yao CC; Han LW; Han CP
J Cutan Pathol; 2010 Oct; 37(10):1123-4. PubMed ID: 20175827
[No Abstract] [Full Text] [Related]
2. Utility of p63 in the differential diagnosis of atypical fibroxanthoma and spindle cell squamous cell carcinoma.
Gleason BC; Calder KB; Cibull TL; Thomas AB; Billings SD; Morgan MB; Hiatt KM; Smoller BR
J Cutan Pathol; 2009 May; 36(5):543-7. PubMed ID: 19476522
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical distinction of cutaneous spindle cell carcinoma.
Morgan MB; Purohit C; Anglin TR
Am J Dermatopathol; 2008 Jun; 30(3):228-32. PubMed ID: 18496422
[TBL] [Abstract][Full Text] [Related]
4. The murine monoclonal antibody anti-cytokeratin CAM 5.2 is specific for intracellular cytokeratin 8, not cytokeratin 18.
Cheng WC; Hsu JD; Yao CC; Han CP
J Thorac Cardiovasc Surg; 2010 Jun; 139(6):1674-5; author reply 1675. PubMed ID: 20494206
[No Abstract] [Full Text] [Related]
5. The predictive ability of a CK5/p63/CK8/18 antibody cocktail in stratifying breast papillary lesions on needle biopsy: an algorithmic approach works best.
Reisenbichler ES; Adams AL; Hameed O
Am J Clin Pathol; 2013 Dec; 140(6):767-79. PubMed ID: 24225742
[TBL] [Abstract][Full Text] [Related]
6. Anti-Cytokeratin (CAM5.2) reagent directed against cytokeratin 8, not cytokeratin 18. Comment on "Improving staging accuracy in colon and rectal cancer by sentinel lymph node mapping: a comparative study. Eur J Surg Oncol. 2009; 35: 1065-1070.".
Lin CK; Yao CC; Tseng SW; Han CP
Eur J Surg Oncol; 2010 Apr; 36(4):428; author reply 429. PubMed ID: 20133104
[No Abstract] [Full Text] [Related]
7. Anticytokeratin CAM5.2 is not synonymous with CK8/18 monoclonal antibody; and anticytokeratin CAM5.2 can be a marker for cytokeratin 8 but not for cytokeratin 18 and 19.
Han CP; Hsu JD; Li YJ
Am J Surg Pathol; 2010 Apr; 34(4):595; author reply 595-6, 596. PubMed ID: 20154593
[No Abstract] [Full Text] [Related]
8. Cytokeratin 8/18 monoclonal antibody was dissimilar to anti-cytokeratin CAM 5.2. Comment on: "A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother Pharmacol. 2010; 65(6): 1009-1021".
Wang SC; Chen FL; Lin WL; Wang PH; Han CP
Cancer Chemother Pharmacol; 2011 Jan; 67(1):243-4; author reply 245. PubMed ID: 21153823
[No Abstract] [Full Text] [Related]
9. The role of CD10 in distinguishing atypical fibroxanthoma from sarcomatoid (spindle cell) squamous cell carcinoma.
Wieland CN; Dyck R; Weenig RH; Comfere NI
J Cutan Pathol; 2011 Nov; 38(11):884-8. PubMed ID: 21883368
[TBL] [Abstract][Full Text] [Related]
10. Anti-cytokeratin CAM5.2 is not a monoclonal antibody against cytokeratin 8/18.
Hsu JD; Yao CC; Han LW; Han CP
Clin Exp Dermatol; 2010 Aug; 35(6):672-3. PubMed ID: 20337654
[No Abstract] [Full Text] [Related]
11. Significant high expression of cytokeratins 7, 8, 18, 19 in pulmonary large cell neuroendocrine carcinomas, compared to small cell lung carcinomas.
Nagashio R; Sato Y; Matsumoto T; Kageyama T; Satoh Y; Ryuge S; Masuda N; Jiang SX; Okayasu I
Pathol Int; 2010 Feb; 60(2):71-7. PubMed ID: 20398190
[TBL] [Abstract][Full Text] [Related]
12. Squamous cell carcinomas with single cell infiltration: a potential diagnostic pitfall and the utility of MNF116 and p63.
Ko CJ; McNiff JM; Glusac EJ
J Cutan Pathol; 2008 Apr; 35(4):353-7. PubMed ID: 18333895
[TBL] [Abstract][Full Text] [Related]
13. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
Tamas EF; Epstein JI
Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
[TBL] [Abstract][Full Text] [Related]
14. [The use of monoclonal antibodies to cytokeratin peptides for the diagnosis of basal cell carcinoma of the skin].
Petrov SV; Raĭkhlin NT; Serre G
Arkh Patol; 1991; 53(6):7-11. PubMed ID: 1719950
[TBL] [Abstract][Full Text] [Related]
15. The expression of p63 and cytokeratin 5 in mixed tumors of the canine mammary gland provides new insights into the histogenesis of these neoplasms.
Ramalho LN; Ribeiro-Silva A; Cassali GD; Zucoloto S
Vet Pathol; 2006 Jul; 43(4):424-9. PubMed ID: 16846983
[TBL] [Abstract][Full Text] [Related]
16. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas.
Kaufmann O; Fietze E; Mengs J; Dietel M
Am J Clin Pathol; 2001 Dec; 116(6):823-30. PubMed ID: 11764070
[TBL] [Abstract][Full Text] [Related]
17. CD10-positive myxofibrosarcomas: a pitfall in the differential diagnosis of atypical fibroxanthoma.
Clarke LE; Frauenhoffer E; Fox E; Neves R; Bruggeman RD; Helm KF
J Cutan Pathol; 2010 Jul; 37(7):737-43. PubMed ID: 20175824
[TBL] [Abstract][Full Text] [Related]
18. True cytokeratin 8/18 immunohistochemistry is of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study.
Hsu JD; Yao CC; Lee MY; Kok LF; Wang PH; Tyan YS; Han CP
Int J Gynecol Pathol; 2010 May; 29(3):282-9. PubMed ID: 20407331
[TBL] [Abstract][Full Text] [Related]
19. Ectopic coexpression of keratin 8 and 18 promotes invasion of transformed keratinocytes and is induced in patients with cutaneous squamous cell carcinoma.
Yamashiro Y; Takei K; Umikawa M; Asato T; Oshiro M; Uechi Y; Ishikawa T; Taira K; Uezato H; Kariya K
Biochem Biophys Res Commun; 2010 Aug; 399(3):365-72. PubMed ID: 20659422
[TBL] [Abstract][Full Text] [Related]
20. Adenosquamous carcinoma: a report of nine cases with p63 and cytokeratin 5/6 staining.
Ko CJ; Leffell DJ; McNiff JM
J Cutan Pathol; 2009 Apr; 36(4):448-52. PubMed ID: 19278431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
